The Obama administration asked a top federal appeals court to reverse a recent bombshell ruling that threatens to cripple Obamacare.» Read More
The uninsured rate in the US has fallen due to Obamacare, but the wide ranges of rates in individual states could actually grow wider.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
The British Medical Association voted on Tuesday in favor of a lifelong ban on cigarette sales to people born after 2000.
A longtime contraction in employer health-care spending is set to end in 2015 and resume an upward trend, according to a forecast.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
A government agency is claiming that the VA's own investigation of itself holds contradictions, CNBC has learned.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Expanding Medicaid eligibility will significantly affect uninsured rates in seven major cities, and bring them billions in federal money, according to a study.
Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.
Genetics startup 23andMe said it is one step closer to resuming sales of its full-fledged health product.
Wealthy Americans worry about the impact of high health care costs in old age, and see it as one of the biggest risks to their financial security.
People who had their old health care plans canceled aren't necessarily paying higher premiums under Obamacare, according to a Kaiser Family Foundation survey.
Prosecutors have issued subpoenas in an investigation into whether congressional staff tipped stock traders to a change in health-care policy. The WSJ reports.
Senators criticized Dr. Mehmet Oz during a hearing on false diet-product ads on Tuesday, but does he control the "Dr. Oz Effect?"
People who receive subsidies and opted for the second-cheapest group HealthCare.gov plans now pay just $69 per month on average in premiums.
ZocDoc is the new king of New York start-ups.
Mehmet Oz acknowledged that his backing of so called miracle weight loss products has caused trouble to for the FTC, Consumerist reports.
Electronic cigarettes, promoted as a healthier alternative to tobacco, are getting powerful new backers: big tobacco firms. NYT reports.
Get the best of CNBC in your inbox